Cargando…

The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups

OBJECTIVE: The aim of the current study was to explore the association between age and outcomes in breast cancer. METHODS: Patients during 2010–2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and breast cancer-specific death (BCSD) wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Hongjuan, Ge, Chenyang, Lin, Haiping, Zhou, Shishi, Tang, Wanfen, Wang, Qinghua, Zhang, Xia, Jin, Xiayun, Xu, Xifeng, Du, Jinlin, Fu, Jianfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847906/ https://www.ncbi.nlm.nih.gov/pubmed/36652446 http://dx.doi.org/10.1371/journal.pone.0280474

Ejemplares similares

A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation
por: Zhou, Shishi, et al.
Publicado: (2021)

The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China
por: Zhou, Shishi, et al.
Publicado: (2023)

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report
por: Zheng, Hongjuan, et al.
Publicado: (2020)

Impact of old age on resectable colorectal cancer outcomes
por: Fu, Jianfei, et al.
Publicado: (2019)

A Prediction Model for Chemotherapy-Induced Thrombocytopenia Based on Real-World Data and a Close Relationship Between AST/ALT Ratio and Platelet Count in Patients with Solid Tumors
por: Song, Bingxin, et al.
Publicado: (2022)

Higher Levels of Tumour-Infiltrating Lymphocytes (TILs) are Associated with a Better Prognosis, While CDK5 Plays a Different Role Between Nonmetastatic and Metastatic Colonic Carcinoma
por: Wang, Qinghua, et al.
Publicado: (2023)

Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment
por: Zhang, Xia, et al.
Publicado: (2023)

Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death
por: Fu, Jianfei, et al.
Publicado: (2019)

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022)

De-escalating chemotherapy for stage II colon cancer?
por: Fu, Jianfei, et al.
Publicado: (2019)

Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer
por: Zhao, Xiaoya, et al.
Publicado: (2020)

Serine Metabolism Regulates YAP Activity Through USP7 in Colon Cancer
por: Zhao, Xiaoya, et al.
Publicado: (2021)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update
por: Mohanty, Swati Sucharita, et al.
Publicado: (2020)

The value of PET/CT for the diagnosis and evaluation of immunotherapy in occult primary renal cell carcinoma: a case report
por: Jiang, Ting, et al.
Publicado: (2023)

Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
por: Chen, Mengdi, et al.
Publicado: (2022)

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
por: Norton, Nadine, et al.
Publicado: (2013)

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019)

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
por: Yang, Ziyan, et al.
Publicado: (2020)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021)

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
por: Schwartzberg, Lee, et al.
Publicado: (2020)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
por: Park, Woong Ki, et al.
Publicado: (2023)

What factors are associated with the poor prognosis of anal adenocarcinoma compared with low-lying rectal adenocarcinoma based on a population analysis: A propensity score matching study
por: Wang, Qinghua, et al.
Publicado: (2019)

Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
por: McGuire, Andrew, et al.
Publicado: (2017)

Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients
por: Mirmalek, Seyed Abbas, et al.
Publicado: (2014)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2
por: Lindsten, Therése, et al.
Publicado: (2017)

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features
por: Benefield, Halei C, et al.
Publicado: (2020)

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021)

Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours
por: Velaga, Ravi, et al.
Publicado: (2022)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
por: Kuo, Wen-Ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vpr1iaj2f1sfbp4s7t2apk2igk